Senem Aykul
Skeletal Diseases TFA, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
Senem Aykul, The author is an employee of Regeneron Pharmaceuticals, Inc. Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..
Richard A Corpina
Skeletal Diseases Therapeutic Focus Area, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
No competing interests declared.
Erich J Goebel
Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati, Cincinnati, United States
Competing interests
No competing interests declared.
Camille J Cunanan
Skeletal Diseases TFA, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
No competing interests declared.
Alexandra Dimitriou
Skeletal Diseases Therapeutic Focus Area, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
No competing interests declared.
Hyonjong Kim
Skeletal Diseases Therapeutic Focus Area, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
Hyonjong Kim, The author is an employee of Regeneron Pharmaceuticals, Inc. Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..
Qian Zhang
Skeletal Diseases Therapeutic Focus Area, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
Qian Zhang, The author is an employee of Regeneron Pharmaceuticals, Inc. Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..
Ashique Rafique
Therapeutic Antibodies, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
Ashique Rafique, The author is an employee of Regeneron Pharmaceuticals, Inc. Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..
Raymond Leidich
Bioassay, Molecular Biology, and Protein Development, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
Raymond Leidich, The author is an employee of Regeneron Pharmaceuticals, Inc. Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..
Xin Wang
Bioassay, Molecular Biology, and Protein Development, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
Xin Wang, The author is an employee of Regeneron Pharmaceuticals, Inc. Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..
Joyce McClain
Genome Engineering Technologies, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
Joyce McClain, The author is an employee of Regeneron Pharmaceuticals, Inc. Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..
Johanna Jimenez
Skeletal Diseases Therapeutic Focus Area, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
Johanna Jimenez, The author is an employee of Regeneron Pharmaceuticals, Inc. Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..
Kalyan C Nannuru
Skeletal Diseases Therapeutic Focus Area, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
Kalyan C Nannuru, The author is an employee of Regeneron Pharmaceuticals, Inc. Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..
Nyanza J Rothman
Skeletal Diseases Therapeutic Focus Area, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
Nyanza J Rothman, The author is an employee of Regeneron Pharmaceuticals, Inc. Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..
John B Lees-Shepard
Skeletal Diseases Therapeutic Focus Area, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
John B Lees-Shepard, The author is an employee of Regeneron Pharmaceuticals, Inc. Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..
Erik Martinez-Hackert
Michigan State University, East Lansing, United States
Competing interests
No competing interests declared.
Andrew J Murphy
Research & Development, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
Andrew J Murphy, The author is an employee of Regeneron Pharmaceuticals, Inc. Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..
Thomas B Thompson
Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati, Cincinnati, United States
Competing interests
No competing interests declared.
Aris N Economides
Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
Aris N Economides, The author is an employee of Regeneron Pharmaceuticals, Inc. Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..
Vincent Idone
Skeletal Diseases Therapeutic Focus Area, Regeneron Pharmaceuticals, Tarrytown, United States
Competing interests
Vincent Idone, The author is an employee of Regeneron Pharmaceuticals, Inc. Regeneron is currently developing a monoclonal antibody that neutralizes Activin A (REGN2477) as a potential therapy in fibrodysplasia ossificans progressiva (see https://clinicaltrials.gov/ct2/show/NCT03188666)..
The authors declare that there was no funding for this work.
Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols.
© 2020, Aykul et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.